Home
About Us
Management
Thrust Areas
Disclaimer
Dr Boominathan’s Quotes
Ideas
Bio-Med Ideas
Ideas for Free
Bio-Pharma/Med Ideas
Audience Profile
Bio-Medical Ideas-7,900+
Bio-Med Res Grants Aid
p63 and p73 Community
How p63/p73/p53 Field Progresses
Noble Laureate’s work tracked by GBMD
Ideas were viewed by World’s Best 10 Universities
Submit your Ideas
miRNA Therapeutics
Intellectual Property Development
Licensing Opportunities
Partnerships
Investor opportunities
Educational Tools
Scientific Resources
Research
Research Focus
Research Themes
Research – II
Dr Boomi’s Contributions (Res)
Dr Boomi’s caliber (Sci)
Conference publications
Research Publications
Research Training
Ph.D/M.D/M.Tech Mentor
What Scientists Saying
Peer/Manuscript Review
Press/Media Release
Conferences/Meetings
B-MERIIT
Introduction
Founder
What We Assure
M.S program
M.S in Molecular Cancer Biology
M.S in Stem cell Biology & Regenerative Medicine
M.S in Mol. Medicine
M.S in Genome Biology
M.S in Bio-Medical Sciences
Model Building & Model Laboratory
Investor opportunities
Logo
Career guidance
Admission Details
Registration
Terms and conditions
Career/Opportunities
Contact Us
Therapeutic insights into the treatment of NIDDM/T2D: ING1b decreases reprogramming of adult pancreatic ductal cells into α, δ, and β cells via down regulation of Ngn3, 19/August/2014, 10.26 am
Insights into weight-loss therapy: MiRNA-125b inhibits hepatic steatosis and inactivates weight gain mechanisms via down regulation of Nocturnin, 19/August/2014, 09.54 am
August 19, 2014
AntagomiR-based treatment for T2D: MiRNA-1 decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1, Genome-2-Bio-Medicine Discovery center (GBMD), 19/08/2014, 10.51 am
August 19, 2014
0
Published by
admin_auro
at
August 19, 2014
Categories
Uncategorized
Tags
admin_auro
Comments are closed.